Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKT-IN-1 (AZD-26) 是一种变构的 AKT 抑制剂,其 IC50=1.042 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 947 | 现货 | ||
2 mg | ¥ 1,320 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,960 | 现货 | ||
50 mg | ¥ 7,880 | 现货 | ||
100 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,580 | 现货 |
产品描述 | AKT-IN-1 (AZD-26) is an allosteric AKT inhibitor (IC50: 1.04 μM). |
靶点活性 | Akt (allosteric):1.04 μM |
体外活性 | AZD-26 is able to potently inhibit phosphorylation of AKT in cells at both Thr308 (IC50: 0.422 μM) and Ser473 (IC50: 0.322 μM). AZD-26 inhibits the phosphorylation of ribosomal protein S6, a downstream effector of the PI3K-AKT pathway. AZD-26 potently inhibits the phosphorylation of PRAS40 [1]. |
体内活性 | The effects of AZD-26 in vivo are characterized by measuring the pharmacodynamic activity of AZD-26 in a BT474c breast adenocarcinoma xenograft model. Following acute doses of 100 and 200 mg/kg, AZD-26 potently inhibits the phosphorylation of its downstream substrate GSK3β as well as the phosphorylation of AKT (Ser473), with a potency consistent with its pharmacokinetic profile. The in vivo activity of AZD-26 is further characterized by measuring the effects on the growth of tumour cell xenografts. Continuous (daily) oral dosing of AZD-26 (100 and 200 mg/kg) to nude mice bearing BT474c breast adenocarcinoma xenografts results in inhibition of tumour growth in a dose-dependent manner. When dosed at 200 mg/kg daily, AZD-26 causes significant tumour growth inhibition[1]. |
别名 | AZD26, AZD-26, 6-[4-(1-氨基环丁基)苯基]-5-苯基-3-吡啶甲酰胺, AZD 26 |
分子量 | 343.42 |
分子式 | C22H21N3O |
CAS No. | 1357158-81-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 24 mg/mL, Sonication is recommended.
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AKT-IN-1 1357158-81-6 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt PKB AZD26 AZD-26 inhibit Protein kinase B 6-[4-(1-氨基环丁基)苯基]-5-苯基-3-吡啶甲酰胺 AKT IN 1 AKTIN1 Inhibitor AZD 26 inhibitor